Back to Journals » Vascular Health and Risk Management » Volume 13

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
Total article views | Abstract views | HTML views | PDF downloads | Totals | |
---|---|---|---|---|---|
5,308 | Dovepress* | 3,915 | 647+ | 1,375 | 4,562 |
PubMed Central* | 0 | 746 | 235 | 746 | |
Totals | 3,915 | 1,393 | 1,610 | 5,308 | |
*Since 6 July 2017 +Since July 2016 |
View citations on PubMed Central and Google Scholar